Open in app

The WHO has put a halt to the distribution of Covaxin through UN agencies.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - World Health Organization)

The WHO has temporarily halted the delivery of Bharat Biotech's COVID vaccine, Covaxin, to allow the company to update its facilities and rectify flaws discovered during a recent inspection. According to a statement released by the WHO, the suspension was prompted by the findings of its post-EUL (emergency use authorization) inspection, as well as the necessity to improve processes and facilities to address previously discovered GMP (good manufacturing practise) flaws. The vaccination certificates provided to the millions who have received Covaxin are still valid because there is no effect on the vaccine's effectiveness or safety. The business has announced a temporary halt in Covaxin manufacturing in order to focus on upcoming facility maintenance, process, and facility optimization efforts. While the business claimed on Sunday it had nothing new to add to the previous statement, it did say that changes were needed since all existing facilities were repurposed for the manufacturing of Covaxin, with continuous production for the last year, to address the public health emergency of COVID-19.

Reference: -